|
Viel ist es nicht Transgenomic Inc. and Geron Corporation Sign Licensing Agreement Covering Novel Class of Synthetic Nucleic Acids Wednesday June 4, 7:31 am ET Agreement Will Enable Transgenomic to Manufacture Phosphoramidate and Thio-Phosphoramidate Oligonucleotides for Diagnostic and Therapeutic Applications OMAHA, Neb. & MENLO PARK, Calif.--(BUSINESS WIRE)--June 4, 2003-- Transgenomic Inc. (Nasdaq:TBIO - News) and Geron Corporation (Nasdaq:GERN - News) announced today that they have entered into an expanded licensing agreement covering manufacture of phosphoramidate and thio-phosphoramidate oligonucleotides. Under the non-exclusive license agreement, Transgenomic gains rights under the patent estate acquired by Geron in 2002 from Lynx Therapeutics Inc. to manufacture phosphoramidate-based oligonucleotides, as well as the chemical building blocks required for their synthesis, for use in diagnostic and therapeutic applications. This represents an extension of Transgenomic`s prior license covering manufacture of these compounds for research applications. In addition to receiving royalties on products for research use as provided in the original agreement, Geron will also receive a royalty on sales of diagnostic and therapeutic products under the expanded agreement. ADVERTISEMENT ATTENTION ACTIVE TRADERS · 30 commission-free trades New account special offer · Enjoy FREE real-time data Get Ameritrade Streamer®. · Join Ameritrade Apex Now trade first class See all that Ameritrade offers Open your account now Phosphoramidate-based oligonucleotides represent a new class of synthetic nucleic acids that have demonstrated a number of potential advantages over earlier-generation oligonucleotide chemistries, including enhanced sequence-specific DNA and RNA binding activity, a high resistance to degradation, and improved cellular uptake and biodistribution. These properties offer significant potential for the development of improved synthetic nucleic acid molecules to be used in both therapeutic and diagnostic applications. Transgenomic currently supplies the modified building block compounds that Geron uses to synthesize novel therapeutic thio-phosphoramidate oligonucleotides that target cancer cells by inhibiting telomerase. Collin D`Silva, Transgenomic`s CEO, commented, "Biopharmaceutical companies such as Geron have a need to adapt cutting-edge developments in nucleic acid chemistry for use in production-scale processes. We can offer added value by applying our expertise to help facilitate this important transition." D`Silva added, "In addition, our world-class nucleic acid chemistry R&D team enables us to fully support the adaptation of next-generation nucleic acid chemistries for use in a variety of potential diagnostic and therapeutic applications. Extension of our license from Geron to include manufacture of phosphoramidate-based oligonucleotides and their precursors for therapeutic and diagnostic use will allow us to offer this novel chemistry to our biopharma and diagnostics customers." "The expansion of Geron`s license agreement with Transgenomic represents a step in our strategy to make phosphoramidate-based oligonucleotides and their monomer building blocks available to other biotechnology and pharmaceutical companies for their drugs," said David L. Greenwood, Geron`s chief financial officer. He noted, "This technology is state-of-the-art and has significant advantages over alternative chemistries. We are using it for our own anti-cancer oligonucleotide drugs, and we expect it to be applied in a broad range of therapeutic products, developed by us and by other companies." About Transgenomic gruss meislo |
|
| aus der Diskussion: | Geron mit Hammernews!! |
| Autor (Datum des Eintrages): | meislo (04.06.03 17:57:14) |
| Beitrag: | 144 von 3,090 (ID:9653120) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |